RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program

New York, NY – May 21, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Dr. Johanna Bendell, Director of the Drug Development Unit at Sarah Cannon Research Center in Nashville, will present an oral abstract related to the RGX-202 program at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The meeting is scheduled to take place May 29 – 31, 2020.

The details of Rgenix’s presentation are as follows:

Event: 2020 ASCO Virtual Scientific Program

Date: May 29, 2020

Time: 8:00 AM EDT (available for download)

Description: Abstract #3504, “Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.”


RGENIX, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. RGENIX identifies novel cancer targets using a microRNA based target discovery platform originally developed by RGENIX’s scientific co-founders at The Rockefeller University and now exclusively licensed to RGENIX. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments,LLC, and the Partnership Fund for New York City. For more information, please visit www.rgenix.com.

About RGX-202

RGX-202 is a small molecule that inhibits a novel cancer metabolism pathway involved in supplying energy to cancer cells. The target of RGX-202, the SLC6a8/CKB pathway, is over-expressed in several prevalent cancer types, including KRAS mutant colorectal cancer. RGX-202 has demonstrated anti-tumor activity in preclinical studies, both as a single agent as well as in combination with standard-of-care therapies.

Media Contact:

Media Contact:
Jeanene Timberlake